A Rare Case of Daratumumab-Associated Encephalopathy in Multiple Myeloma

References

• Mateos MV, Dimopoulos MA, Cavo M et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N. Engl. J. Med. 2018;378(6):518–528 doi: 10.1056/NEJMoa1714678.
   PubMed Web of Science ®Google Scholar
• Chari A, Martinez-Lopez J, Mateos MV et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood 2019;134(5):421–431. doi: 10.1182/blood.2019000722.
   PubMed Web of Science ®Google Scholar
• Facon T, Kumar S, Plesner T et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N. Engl. J. Med. 2019;380(22):2104–2115. doi: 10.1056/NEJMoa1817249.
   PubMed Web of Science ®Google Scholar
• Nooka AK, Kaufman JL, Hofmeister CC et al. Daratumumab in multiple myeloma. Cancer 2019;125(14):2364–2382. doi: 10.1002/cncr.32065.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Bögels M et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7(2):311–321. doi: 10.1080/19420862.2015.1007813.
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N. Engl. J. Med. 2016;375(8):754–766. doi: 10.1056/NEJMoa1606038.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Oriol A, Nahi H et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N. Engl. J. Med. 2016;375(14):1319–1331. doi: 10.1056/NEJMoa1607751.
   PubMed Web of Science ®Google Scholar
• Guo Y, Tian X, Wang X et al. Adverse effects of immunoglobulin therapy. Front. Immunol. 2018;9:1299. doi: 10.3389/fimmu.2018.01299.
   PubMed Web of Science ®Google Scholar
• Angel MJ, Young GB. Metabolic encephalopathies. Neurol. Clin. 2011;29(4):837–882. doi: 10.1016/j.ncl.2011.08.002.
   PubMed Web of Science ®Google Scholar
• Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914–925. doi: 10.1016/S1474-4422(15)00111-8.
   PubMed Web of Science ®Google Scholar
• Laurent C, Capron J, Quillerou B et al. Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): characteristics, treatment and outcome in 251 cases from the literature. Autoimmun. Rev. 2016;15(12):1129–1133. doi: 10.1016/j.autrev.2016.09.008.
   PubMed Web of Science ®Google Scholar
• Gofton TE, Young GB. Sepsis-associated encephalopathy. Nat. Rev. Neurol. 2012;8(10):557–566. doi: 10.1038/nrneurol.2012.183.
   PubMed Web of Science ®Google Scholar
• Cuzzubbo S, Javeri F, Tissier M et al. Neurological adverse events associated with immune checkpoint inhibitors: review of the literature. Eur. J. Cancer 2017;73:1–8. doi: 10.1016/j.ejca.2016.12.001.
   PubMed Web of Science ®Google Scholar
• Williams TJ, Benavides DR, Patrice KA et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol. 2016;73(8):928–933. doi: 10.1001/jamaneurol.2016.1399.
   PubMed Web of Science ®Google Scholar
• Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N. Engl. J. Med. 2018;378(2):158–168. doi: 10.1056/NEJMra1703481.
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Nagasawa H, Katagiri Y et al. Atezolizumab-associated encephalitis in metastatic lung adenocarcinoma: a case report. J. Med Case Rep. 2020;14(1):88. doi: 10.1186/s13256-020-02411-y.
   PubMedGoogle Scholar
• Levine JJ, Somer RA, Hosoya H et al. Atezolizumab-induced encephalitis in metastatic bladder cancer: a case report and review of the literature. Clin. Genitourin. Cancer 2017;15(5):e847–e849. doi: 10.1016/j.clgc.2017.03.001.
   PubMed Web of Science ®Google Scholar
• Stuby J, Herren T, Schwegler Naumburger G et al. Immune checkpoint inhibitor therapy-associated encephalitis: a case series and review of the literature. Swiss Med. Wkly 2020;150:w20377. doi: 10.4414/smw.2020.20377.
   PubMed Web of Science ®Google Scholar
• Zafar Z, Vogler C, Hudali T et al. Nivolumab-associated acute demyelinating encephalitis: a case report and literature review. Clin. Med. Res. 2019;17(1–2):29–33. doi: 10.3121/cmr.2019.1417.
   PubMed Web of Science ®Google Scholar
• Varga G, Mikala G, Gopcsa L et al. Multiple myeloma of the central nervous system: 13 cases and review of the literature. J. Oncol. 2018;2018:3970169. doi: 10.1155/2018/3970169.
   PubMed Web of Science ®Google Scholar
• Elhassadi E, Murphy M, Hacking D et al. Durable treatment response of relapsing CNS plasmacytoma using intrathecal chemotherapy, radiotherapy, and daratumumab. Clin. Case Rep. 2018;6(4):723–728. doi: 10.1002/ccr3.1451.
   PubMedGoogle Scholar
• Badros A, Singh Z, Dhakal B et al. Marizomib for central nervous system-multiple myeloma. Br. J. Haematol. 2017;177(2):221–225. doi: 10.1111/bjh.14498.
   PubMed Web of Science ®Google Scholar
• Dapkevičiūtė-Purlienė A, Augustinavičius V, Žučenka A. Case report: relapsed/refractory extranodal natural killer/T-cell lymphoma nasal type with extensive central nervous system involvement. Pathol. Oncol. Res. 2023;28:1610866. doi: 10.3389/pore.2022.1610866.
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J. Immunol. 2011;186(3):1840–1848. doi: 10.4049/jimmunol.1003032.
   PubMed Web of Science ®Google Scholar
• Tun HW, Johnston PB, DeAngelis LM et al. Phase I study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma. Blood 2018;132(21):2240–2248. doi: 10.1182/blood-2018-02-835496.
   PubMed Web of Science ®Google Scholar
• Ratuszny D, Skripuletz T, Wegner F et al. Case Report: Daratumumab in a Patient With Severe Refractory Anti-NMDA Receptor Encephalitis. Front Neurol. 2020;11:602102. doi: 10.3389/fneur.2020.602102.
   PubMed Web of Science ®Google Scholar
• Scheibe F, Ostendorf L, Prüss H et al. Daratumumab for treatment-refractory antibody-mediated diseases in neurology. Eur. J. Neurol. 2022;29(6):1847–1854. doi: 10.1111/ene.15266.
   PubMed Web of Science ®Google Scholar